The introduction of sodium-glucose cotransporter 2 inhibitors (SGLT-2is), a novel class of oral antidiabetic drugs (OADs), has caused a paradigm shift in the treatment strategies for patients with type 2 diabetes mellitus (T2DM). Here, SLC5A2 is linked to diabetes mellitus.